Annals of Cancer Research and Therapy
Online ISSN : 1880-5469
Print ISSN : 1344-6835
ISSN-L : 1344-6835
Original Articles
A Phase III study of combination therapy of the oral fluorinated pyrimidine compound tegafur-uracil (UFT) with low dose cisplatin compared with UFT alone in patients with locally advanced gastric cancer as postoperative adjuvant chemotherapy
Akira GochiShigetoyo SajiJunichi SakamotoKoichi HirataSuketami TominagaYoshiyuki YamaguchiMasahiko ShibataYoshiki KaiHiromi TanemuraTetsuhiko Shirasaka
Author information
JOURNAL FREE ACCESS

2012 Volume 20 Issue 1 Pages 17-23

Details
Abstract

Background: While surgery remains the sole mainstay of any curative treatment for gastric cancer, the relapse rate is high and survival remains low even after surgical resection with curative intent.
Methods: Based on biochemical modulation theory, this trial was assigned for gastric cancer patients as post operative adjuvant setting with at least 4 cycles of either UFT (UF group) or 5-FU plus low dose cisplatin (CF) and UFT (CD group). The planned 4 cycles of CF treatment was received by 95% of patients in the CD group. One year of UFT was received by 93 (99%) and 91 (97%) of the patients in the groups administered UFT and cisplatin/5FU+UFT, respectively.
Results: The result suggests better 5 year survival rate in the combination treatment group, with a reduction in risk of 13%. 5 year DFS was also showed benefit of combination therapy over UFT alone, with a reduction in risk of 15%.
Conclusion: These findings from our phase III randomized trial suggest that low dose cisplatin+5-FU followed by UFT may hold promise as a treatment for curatively resected locally advanced gastric cancer patients.

Content from these authors
© 2012 by The Japanese Society of Strategies for Cancer Research and Therapy
Previous article Next article
feedback
Top